Discover opportunities months before the RFP drops
Learn more →Retrieving contract details... Hang tight!
See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis
This contract includes 1 purchase order from Dec 29, 2022 to Dec 29, 2022
| Buyer | Vendor | Issued Date | Quantity |
|---|---|---|---|
| Office of Acquisition Managementt Policy | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Dec 29, 2022 | 1 |
Full Purchase Intelligence Available
Get complete pricing, descriptions, and financial details for all 1 purchase orders
Unlock Full Details →See what competitors charge and their contract structure
Spot renewal opportunities 6-12 months before expiration
Analyze buyer's purchasing history and vendor preferences
Track expiration dates across all your target accounts
Reach decision-makers before renewal with competitive intel
Our customers win 3x more contract renewals and replacements
No public files available for this contract.
Contract documentation may be available through official government sources or agency portals. Starbridge can help you track down and retrieve these files.
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
Effective Date
Sep 26, 2019
Expires
Effective: Sep 26, 2019
THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE.
ActiveTHE OVERALL OBJECTIVE OF THIS SOW IS TO CREATE A PARTNERSHIP BETWEEN THE AGREEMENT RECIPIENT, DUKE UNIVERSITY ON BEHALF OF DUKE CLINICAL RESEARCH INSTITUTE (DCRI), AND BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) TO ENHANCE INNOVATI
Effective Date
Sep 29, 2024
Expires
Effective: Sep 29, 2024
THE OVERALL OBJECTIVE OF THIS SOW IS TO CREATE A PARTNERSHIP BETWEEN THE AGREEMENT RECIPIENT, DUKE UNIVERSITY ON BEHALF OF DUKE CLINICAL RESEARCH INSTITUTE (DCRI), AND BIOMEDICAL ADVANCED RESEARCH AND DEVELOPMENT AUTHORITY (BARDA) TO ENHANCE INNOVATI
ActiveTHE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
Effective Date
Sep 30, 2021
Expires
Effective: Sep 30, 2021
THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. THESE VACCINES ARE BASED ON RECOMBINANT EXPRESSION OF FILOVIRUS GLYCOPROTEINS IN
ActiveOXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.
Effective Date
Sep 30, 2025
Expires
Effective: Sep 30, 2025
OXIVAX - AOI #28: INFLUENZA VACCINE INNOVATION. ADVANCING METAGENOMIC NEXT-GENERATION SEQUENCING BASED AGNOSTIC DIAGNOSTICS FOR VIRAL PATHOGENS THE OVERALL OBJECTIVE OF THIS CONTRACT IS TO PREPARE THE IND PACKAGE FOR OVX836+SQ ADJUVANT.
ActiveSee who's winning contracts, track spending trends, and identify your best opportunities before your competition.
Schedule Your Demo →Premium
Clean & enrich your CRM automatically
Premium
Get complete source documentation & analysis